Navigation Links
Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
Date:1/7/2014

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies for the treatment of rare orphan diseases, today announced that Joseph E. Payne, President & CEO will be presenting at the Biotech Showcase in San Francisco on Monday, January 13, 2014 at 11:30 a.m. PST, at the Parc 55 Wyndham Union Square Hotel in Track A - Hearst (3rd Floor). The presentation will provide a corporate overview and summarize the key accomplishments of 2013, including:

  • Development of a novel, potent and safe RNA Therapeutics platform called LUNARTM technology – a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, and microRNA oligotherapeutics
  • Ownership of Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome
  • Key milestones achieved: Superior in vivo potency data, excellent safety profile as demonstrated in a multiple-dose rat toxicology study, high encapsulation efficiency of RNA cargo greater than 95%, and GMP-readiness of the drug product manufacturing process.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Calif., Arcturus Therapeutics is focused on RNA technologies for the treatment of rare diseases and high unmet medical needs. Arcturus has developed of a novel, potent and safe RNA Therapeutics platform called LUNAR TM , a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, and microRNA oligotherapeutics.  The company owns Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome For more information, visit us at www.ArcturusRx.com.

About Biotech ShowcaseTM 2014
Biotech Showcase is an annual investing and partnering benchmark for life science executives and investors devoted to providing private and public biotechnology and life sciences companies, investors and pharmaceutical executives with an opportunity to present and meet in one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world. Now in its Sixth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule face to face partnering meetings and networking. The attendees to the showcase include private and public equity investors, bankers, analysts, biopharmaceutical industry executives and other industry professionals. The event is being held at the Parc 55 Wyndham San Francisco – Union Square.


'/>"/>
SOURCE Arcturus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
5. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
6. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
7. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
8. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
9. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
10. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
11. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... publication of a United States multicenter, prospective clinical study that demonstrates the ... diagnostic test capable of identifying clinically significant acute bacterial and viral respiratory ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):